TODAY'S HEADLINES

FDA approves biosimilar to Humira

FDA's pace of biosimilar approvals is picking up, as it recently approved 2 major drugs for rheumatoid arthritis (RA) and other inflammatory diseases, including adalimumab-atto (Amjevita), a biosimilar to Humira, to treat RA, psoriatic arthritis and other conditions. Read more

Invokamet extended-release approved for diabetes

FDA recently approved an expanded use for Invokamet (Janssen): Invokamet XR, an extended-release combination drug to treat type 2 diabetes. The new once-daily, fixed-dose therapy combines canagliflozin (Invokana) and metformin hydrochloride extended-release medication to improve blood glucose control. Read more

CONTINUING PHARMACY EDUCATION

The role of the community pharmacy team in assisting patients receiving oral anticancer medications

This month's CE activity, "The role of the community pharmacy team in assisting patients receiving oral anticancer medications," is open for pharmacists and pharmacy technicians.
The goal of this activity is to educate pharmacists and pharmacy technicians about oral anticancer medications.
Pharmacists and pharmacy technicians can earn up to 2 hours of CPE credit for completing this knowledge-based activity from the University of Connecticut School of Pharmacy and Drug Topics. More

EDITOR'S PICK

New biosimilar for RA to save millions

FDA's approval of a new biosimilar for rheumatoid arthritis stands to save the US healthcare system millions of dollars. Find out why

September 28, 2016

Related Articles

FDA approves first biosimilar Zarxio

FDA approves long-acting insulin drugs